drugset / Trial / NCT00582140
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
Phase 1
Completed
22 enrolled
University of Wisconsin, Madison
United States Department of Defense · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer. In this study the investigators will be testing the safety of a vaccine that may be able to help the body fight prostate cancer.
Timeline
- Start
- 2005-03
- Primary completion
- 2008-08
- Completion
- 2008-08
Publications
- Results Johnson LE, Olson BM, McNeel DG. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. J Immunother Cancer. 2017 Jul 18;5(1):56. doi: 10.1186/s40425-017-0260-3.
- Tonelli TP, Eickhoff JC, Johnson LE, Liu G, McNeel DG. Long-term follow up of patients treated with a DNA vaccine (pTVG-hp) for PSA-recurrent prostate cancer. Hum Vaccin Immunother. 2024 Dec 31;20(1):2395680. doi: 10.1080/21645515.2024.2395680. Epub 2024 Aug 29.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | pTVG-HP | Vaccine | 100 ug | Intramuscular |
| Subject | pTVG-HP | Vaccine | 500 ug | Intramuscular |
| Subject | pTVG-HP | Vaccine | 1500 ug | Intramuscular |
| Background | rhGM-CSF | Protein / enzyme biologic | 200 ug | Intramuscular |